Ideaya showcases proof-of-concept data in a boost to synthetic lethality play

Amber Tong

Fresh Phase 2 data are adding weight to Ideaya Biosciences’ case for a targeted therapy it believes could be a first-in-class treatment option for certain …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Ideaya showcases proof-of-concept data in a boost to synthetic lethality play

Amber Tong

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

WuXi companies may sell units impacted by Biosecure — report

Biotech's third quarter was relatively bright — with a few caveats

Sanofi sells rare disease drug Enjaymo to Recordati for $825M upfront

BioNTech opens the hood on its AI ambitions, and they're not just for mRNA

EMA reviews hair loss products following concerns about suicidal thoughts

3 Tiers for AAV Potency Assay Development Success

Ideaya show­cas­es proof-of-con­cept da­ta in a boost to syn­thet­ic lethal­i­ty play

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Ideaya showcases proof-of-concept data in a boost to synthetic lethality play